(Q38393995)
Statements
Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease (English)
Robert A Rosenheck
Jody L Sindelar
Edward A Miller
Peter N Tariot
Karen S Dagerman
Sonia M Davis
Peter Rabins
John K Hsiao
Jeffery A Lieberman
Lon S Schneider
Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators